17 Managing skin disease in SLE

levels.[The best therapeutic options in this case will be discussed with the participants during the workshop].We started belimumab and this approach led to improvement of skin and joint manifestations, but in November 2022 she presented inflammatory arthralgias, leukopenia, positive anti-dsDNA (96 KUI/L) and low C3 and C4; SLEDAI-2K 5.She was on prednisone 7.5 mg/day, belimumab 200 mg/week, HCQ 400 mg/ day, MMF 2 g/day.Thus, she was not at target according to the treat-to-target strategy. 3 4[The best therapeutic options in this case will be discussed with the participants during the workshop.]We replaced MMF with methotrexate 15 mg/week with clinical improvement and successful tapering of prednisone to 5 mg/day.